

REMARKS

Claims 1-14 are pending in the application. The Examiner has allowed claims 5-9 and 13. Claims 1 and 14 have been amended.

The Examiner has rejected claims 1-4, 10-12 and 14 under 35 U.S.C. §102(b) as allegedly anticipated by Australian Patent Publication AU-B1-26,024/77. The reference discloses compounds of structural formula where X is nitrogen and R6 is alkyl, cyclohexyl, benzyl, and R5 is either hydrogen or methyl. In view thereof, the present amendment has excluded such compounds. In addition, the present amendment has excluded additional compounds from our previously prior art reference WO 97/33858 which particularly describes a compound where R6 is acetyl when X is nitrogen. Claim 14 has been clarified and made dependent on claim 1.


The rejection of claims 10-12 is not appropriate and should be withdrawn without requiring amendment. The indication for the method claim in claim 10 is not described in any of the prior art references. This indication is related to the diabetic use of claim 6 as illustrated on pages 16, lines 1-7 of the specification.

In view of amended claims 1-14 and the above arguments, the Examiner's rejection should be withdrawn.

All of the pending claims in the present application are now in condition for allowance; prompt passage to issue is earnestly solicited.

Respectfully submitted,

2/25/04
Date


Ronald A. Daignault
Reg. No. 25,968
Merchant & Gould P.C.
P. O. Box 2903
Minneapolis, MN 55402-0903
202.625.8380

